Haemonetics Corporation updated revenue guidance for the fiscal year 2024. For the year, the company expects GAAP total reported revenue growth to be between 10% to 12% against previous guidance of total reported revenue growth to be between 8% to 10% and total organic revenue growth to be between 10% to 12% against previous guidance of total organic revenue growth to be between 8% to 10%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
90.99 USD | +3.80% | +12.00% | +6.41% |
Apr. 04 | Haemonetics Gets FDA Clearance for New TEG 6s Global Hemostasis-HN Cartridge | MT |
Apr. 04 | Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.41% | 4.62B | |
-2.31% | 187B | |
-3.20% | 106B | |
-5.04% | 66.9B | |
+0.20% | 49.45B | |
+17.29% | 48B | |
+4.06% | 40.84B | |
+2.36% | 26.25B | |
+2.07% | 26.48B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- HAE Stock
- News Haemonetics Corporation
- Haemonetics Corporation Updates Revenue Guidance for the Fiscal Year 2024